Control Bionics partners with Double R&D to launch NeuroNode Technology in Japan

Be the First to Comment Read
Sponsored

Control Bionics partners with Double R&D to launch NeuroNode Technology in Japan

More on:
Control Bionics’ NeuroNode Technology
Image source: Company Website

Highlights

  • Control Bionics has signed an agreement with major assistive technology distributor, Double R&D to expand its footprint in Japan.
  • CBL wants people with medical conditions such as ALS, intellectual disability, cerebral palsy, stroke and traumatic brain injuries have greater access to its tech products.
  • The AAC solution will be launched in Japan on the 16th and 17th of April 2022 at KidsFesta in Tokyo.

Control Bionics (ASX:CBL) is all set to launch its NeuroNode Trilogy technology in Japan in partnership with major assistive technology distributor, Double R&D Co Ltd, under an initiative led by CBL’s Japanese executive, Erica Kitayama.

CBL has advanced the deal to provide its technology benefits to Japanese people with medical conditions such as ALS, cerebral palsy, intellectual disability, stroke and traumatic brain injuries.

On back of the launch update on ASX, CBL shares soared more than 14.285% and closed at AU$0.400.

Do read: How Control Bionics (ASX:CBL) can ease the lives of disabled patients     

Specifics of the CBL-Double R&D agreement

Control Bionics to launch NeuroNode Technology in Japan

Image source: © Sjankauskas | Megapixl.com

As per the agreement between the two entities, Double R&D will be the exclusive distributor of Trilogy products and other CBL products in Japan. Double R&D will be placing orders from CBL on the basis of the cost of the products as drafted in the contract. Also, there isn’t any provision for minimum order purchase quantities in the agreement.

On joining hands with Double R&D, CBL CEO Rob Wong said, “We are extremely honoured to be partnering with Double R&D after working diligently with them to localise our NeuroNode Trilogy and software for the Japanese market. We believe there is a significant need for our technology across Japan.”

Control Bionics’ technology will be introduced on the 16th and 17th of April 2022 at KidsFesta in Tokyo, Japan’s largest disability event focused on children.

Read More: Control Bionics’ busy H1 paints bright outlook for FY22   

A glimpse into CBL’s life-changing technology

Control Bionics’ NeuroNode Technology

Image source: Company website

NeuroNode Trilogy system is the world’s fastest and lowest-fatigue communication and control system. It allows non-verbal people with severely impaired movement to control a computer for speech generation, gaming, email and text, with ease and speed.

The 3-in-1 solution is up to 47% faster than traditional eye-gaze systems with significantly less user fatigue. In the initial stage of the partnership, around 30 resellers will be trained on the tech device within the wide network of Double R&D.

Related read: NeuroNode Trilogy: A powerful access method for communication challenges

Exploring the realm of Double R&D

Double R&D has been a leading-edge industrial robot and factory automation equipment manufacturer for over 45 years now. It holds more than 24 years of experience as a distributor of AAC devices to patients having intractable neurological diseases in Japan. Till date, the firm has accomplished more than 3,000 AAC installation experiences in Japanese market.

Here’ what Double R&D President Hiroshi Wada had to say about the newly-built partnership:
“We feel honoured and excited about this opportunity to distribute NeuroNode Trilogy which is innovative and world leading AAC product in Japan. It remains vividly in my memory of the first experience of NeuroNode Trilogy a year ago. We are confident that the users of NeuroNode will experiences their new life and we will bring smile to patients, their family, caretakers and all of their supporters in Japan. We would like Control Bionics to look forward to our success in Japan.”

Also read: How Control Bionics is set to make a strong mark in assistive technology market

Disclaimer

Speak your Mind

Featured Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK